The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment ... are other companies offering treatment for OSA, such as ResMed (RMD) and Inspire Medical Systems (INSP).

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

Inspire is a medical technology ... of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please ...

Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe ...

The company develops minimally invasive solutions for patients with obstructive sleep apnea ... expand Inspire’s total addressable market by causing more people with obesity to seek treatment ...

Inspire Medical Systems (NYSE:INSP – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at KeyCorp in a research note issued to investors on Friday,Benzinga ...